Argent BioPharma has raised US$4.5 million (A$7.3m) through the placement of 11,250,000 shares at US$0.40c (A$0.65c) each, with the proceeds earmarked to advance the firm’s drug development pipeline.

A particular focus will be on progressing Argent’s CannEpil epilepsy treatment and planned clinical studies.

The company is also conducting a strategic review to ensure the long-term sustainability of its operations, following its delisting from the London Stock Exchange, with plans to list in the US.

Greenfern Industries

Greenfern Industries (GFI) has secured a six-month loan facility of NZ$200k plus fees and interest from Emdex Limited. 

GFI told the NZX the loan will provide short-term funding to support its ongoing operations and strategic initiatives. 

Meanwhile, the firm is set to hold a special shareholder meeting to vote on various related party loans and agreements in the coming weeks. 

Prior to launching Cannabiz, Martin was co-founder and CEO of Asia-Pac’s leading B2B media and marketing information brand Mumbrella, overseeing its sale to Diversified Communications in 2017. A journalist...

Leave a comment